Lisa Giulino Roth MD (She/her)
Pediatric Hematologic Oncology
Director, Division of Pediatric Hematology/Oncology, NYU Langone Health
160 E. 32nd Street2nd FloorNew York, NY 10016
Overview of Dr. Roth
Dr. Roth is an internationally recognized pediatric oncologist, physician-scientist, and lymphoma survivor, whose research and clinical expertise focus on B-cell lymphomas affecting children, adolescents, and young adults. Her work has significantly advanced understanding of EBV-associated lymphomas, Hodgkin lymphoma, Burkitt lymphoma, and primary mediastinal B-cell lymphoma. Her NIH-funded research program integrates multi-omic tumor characterization, mechanistic studies, translational research, and leadership of national phase I–III clinical trials.
A graduate of NYU School of Medicine, Dr. Roth trained at Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Memorial Sloan Kettering Cancer Center. She has held major leadership roles within the Children’s Oncology Group and the NCI Clinical Trials Network, including Vice Chair of the Hodgkin Lymphoma Committee and national Principal Investigator for several landmark clinical trials. Her work has been supported by the NIH (K08, R37 MERIT, and U01), the Department of Defense, and multiple national foundations.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2008 - 2011- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2005 - 2008
New York University School of MedicineClass of 2005
Certifications & Licensure
NY State Medical License 2006 - 2027
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 3 citationsGerminal Center Cytokines Driven Epigenetic Control of Epstein-Barr Virus Latency Gene Expression.Liao Yifei, Yan Jinjie, Nina R Beri, Lisa G Roth, Cesarman Ethel
Biorxiv. 2024-01-03 - 13 citationsA Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P. Collins, Toby A. Eyre, Debora Schmitz-Rohmer, William Townsend, Rakesh Popat
Hemasphere. 2021-11-01 - 90 citationsTherapeutic options for CTLA-4 insufficiency.David Egg, Ina Caroline Rump, Noriko Mitsuiki, Jessica Rojas-Restrepo, Maria Elena Maccari
The Journal of Allergy and Clinical Immunology. 2021-06-07
Press Mentions
Dr. Lisa G. Roth Appointed Director of Pediatric Hematology-Oncology at Hassenfeld Children’s Hospital, NYU LangoneMarch 31st, 2026
Lisa G. Roth, MD, Named Director of Pediatric Hematology-Oncology at Hassenfeld Children's Hospital at NYU LangoneMarch 28th, 2026
Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin LymphomaDecember 8th, 2024
Grant Support
- B cell determinants of EBV latencyWEILL MEDICAL COLL OF CORNELL UNIV2022–2027
- Targeting Latency Switch in EBV+ LymphomasWEILL MEDICAL COLL OF CORNELL UNIV2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
